288 related articles for article (PubMed ID: 34603322)
1. The Immunoregulatory Role of the Signal Regulatory Protein Family and CD47 Signaling Pathway in Type 1 Diabetes.
Sharp RC; Brown ME; Shapiro MR; Posgai AL; Brusko TM
Front Immunol; 2021; 12():739048. PubMed ID: 34603322
[TBL] [Abstract][Full Text] [Related]
2. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo.
Legrand N; Huntington ND; Nagasawa M; Bakker AQ; Schotte R; Strick-Marchand H; de Geus SJ; Pouw SM; Böhne M; Voordouw A; Weijer K; Di Santo JP; Spits H
Proc Natl Acad Sci U S A; 2011 Aug; 108(32):13224-9. PubMed ID: 21788504
[TBL] [Abstract][Full Text] [Related]
3. SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation.
Dehmani S; Nerrière-Daguin V; Néel M; Elain-Duret N; Heslan JM; Belarif L; Mary C; Thepenier V; Biteau K; Poirier N; Blancho G; Haspot F
Front Immunol; 2021; 12():732530. PubMed ID: 34925315
[TBL] [Abstract][Full Text] [Related]
4. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
5. Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.
Sugimura-Nagata A; Koshino A; Inoue S; Matsuo-Nagano A; Komura M; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Tsuzuki T; Takahashi S; Kasugai K; Kasai K; Inaguma S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799989
[TBL] [Abstract][Full Text] [Related]
6. Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.
Yang H; Shao R; Huang H; Wang X; Rong Z; Lin Y
Cancer Med; 2019 Aug; 8(9):4245-4253. PubMed ID: 31183992
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism in the innate immune receptor SIRPα controls CD47 binding and autoimmunity in the nonobese diabetic mouse.
Wong AS; Mortin-Toth S; Sung M; Canty AJ; Gulban O; Greaves DR; Danska JS
J Immunol; 2014 Nov; 193(10):4833-44. PubMed ID: 25305319
[TBL] [Abstract][Full Text] [Related]
8. Genetic Control of Splicing at SIRPG Modulates Risk of Type 1 Diabetes.
Smith MJ; Pastor L; Newman JRB; Concannon P
Diabetes; 2022 Feb; 71(2):350-358. PubMed ID: 34799406
[TBL] [Abstract][Full Text] [Related]
9. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
[TBL] [Abstract][Full Text] [Related]
10. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
11. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
12. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
Matozaki T; Murata Y; Okazawa H; Ohnishi H
Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
[TBL] [Abstract][Full Text] [Related]
13. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
14. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
15. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
16. Novel CD47: SIRPα dependent mechanism for the activation of STAT3 in antigen-presenting cell.
Toledano N; Gur-Wahnon D; Ben-Yehuda A; Rachmilewitz J
PLoS One; 2013; 8(9):e75595. PubMed ID: 24073274
[TBL] [Abstract][Full Text] [Related]
17. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation.
Latour S; Tanaka H; Demeure C; Mateo V; Rubio M; Brown EJ; Maliszewski C; Lindberg FP; Oldenborg A; Ullrich A; Delespesse G; Sarfati M
J Immunol; 2001 Sep; 167(5):2547-54. PubMed ID: 11509594
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47.
Hatherley D; Lea SM; Johnson S; Barclay AN
J Biol Chem; 2014 Apr; 289(14):10024-8. PubMed ID: 24550402
[TBL] [Abstract][Full Text] [Related]
19. The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes.
Pearson JA; Wong FS; Wen L
J Autoimmun; 2016 Jan; 66():76-88. PubMed ID: 26403950
[TBL] [Abstract][Full Text] [Related]
20. Phagocytic signaling: you can touch, but you can't eat.
Kinchen JM; Ravichandran KS
Curr Biol; 2008 Jun; 18(12):R521-4. PubMed ID: 18579095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
